Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Investing

No, It’s Not Price Controls: Trump’s Executive Order to Reduce the Prices Medicare Pays for Medicines

by May 12, 2025
May 12, 2025
No, It’s Not Price Controls: Trump’s Executive Order to Reduce the Prices Medicare Pays for Medicines

Michael F. Cannon

Government should not purchase medicines for civilians. Period. The US Medicare and Medicaid programs illustrate why. Medicare pays significantly higher prices for medicines than other government programs. Medicaid likewise overpays for prescription drugs and has spillover effects that increase drug prices for private purchasers. These programs pay excessive prices partly because Congress largely let the pharmaceutical industry write each program’s drug-pricing rules.

Government should get out of the business of purchasing or subsidizing medicines for civilians. In other words, the price that Medicare and Medicaid should be paying for drugs is $0.00. To the extent that Trump’s executive order moves the prices Medicare pays for medicines closer to the ideal price of $0.00, it is a step in the right direction.

It is not a “price control” when the government reduces the prices Medicare pays for drugs. Price controls are coercive restraints government places on private actors. If Medicare pays less for drugs, by contrast, private actors remain free to buy and sell at whatever prices make them happy.

If Congress fears that lower Medicare prices would lead to insufficient pharmaceutical research, development, and innovation, the way to correct that market failure is to adjust the patent system. Medicare is not a drug-innovation program. Moreover, the patent system is constitutional. Medicare is not.

0
FacebookTwitterGoogle +Pinterest
previous post
Trump China tariff truce ignites stock markets – will it also pump up president’s poll numbers?
next post
ICE Agents Routinely Mask Up When Seizing People—That’s Wrong

You may also like

More Bank Lending Won’t Cure China’s Ills

January 31, 2024

The New Deal and Recovery, Part 27: Deposit...

March 28, 2023

Shaken Baby Syndrome: A Hypothesis That Keeps Sending...

December 30, 2024

Making Medicine Cost More Won’t Make America Healthy...

April 14, 2025

You Say You Want Fintech Competition, You Better...

November 26, 2024

Beer, Wine, Whiskey, Cigars, and Cigarettes Are Not...

April 30, 2024

Recent Articles Highlight Jones Act Contributions to Offshore...

January 2, 2024

Steel Prices Continue to Rise Even Before New...

March 3, 2025

NEW POLL: WI, PA, & MI Voters Believe...

September 9, 2024

Inclusionary Zoning and Affordable Housing

November 17, 2023

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • HMRC inheritance tax investigations surge 37% as treasury seeks to plug revenue gap

      June 9, 2025
    • Believ secures £300m to roll out 30,000 public EV charge points across the UK

      June 9, 2025
    • US and China hold London talks to ease trade war tensions

      June 9, 2025
    • British fathers urged to join landmark ‘dad strike’ over poor paternity leave

      June 9, 2025
    • IVF parents should have right to paid fertility leave, says GMB union

      June 9, 2025
    • Reform UK clashes with Bank of England over interest payments to lenders

      June 9, 2025

    Categories

    • Business (8,158)
    • Investing (2,019)
    • Politics (15,571)
    • Stocks (3,136)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved